NASDAQ:VINC Vincerx Pharma Q2 2024 Earnings Results & Report $0.03 0.00 (0.00%) As of 10/12/2026 Vincerx Pharma beat analyst earnings expectations in its Q2 2024 results, released August 8, 2024. The company reported EPS of -$1.00 versus the -$3.40 consensus estimate. Research:Profile Earnings Announcement Details QuarterQ2 2024Report DateAugust 8, 2024TimeAfter Market ClosesConference Call4:00 PM ET Vincerx Pharma EPS ResultsActual EPS-$1.00Consensus EPS -$3.40Beat/MissBeat by +$2.40One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersVincerx Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsVincerx Pharma's next earnings date is estimated for Tuesday, November 10, 2026, based on past reporting schedules. Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Company ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vincerx Pharma Q2 2024 Earnings FAQ Did Vincerx Pharma beat earnings estimates for Q2 2024? Vincerx Pharma (NASDAQ:VINC) reported earnings of -$1.00 per share for Q2 2024, beating the consensus estimate of -$3.40. The report was announced on Thursday, August 8, 2024. When is Vincerx Pharma's next earnings date? Vincerx Pharma's next earnings date is estimated for Tuesday, November 10, 2026. MarketBeat tracks confirmed and estimated earnings dates for Vincerx Pharma on the company's earnings history page. Vincerx Pharma Earnings HeadlinesAntibody Drug Conjugates (ADC) Market Research and Competitive Landscape Report 2026 - Extensive Analysis of Over 180 Companies and More Than 290 DrugsApril 14, 2026 | finance.yahoo.comVincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...July 16, 2025 | gurufocus.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 13 at 1:00 AM | Banyan Hill Publishing (Ad)Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution ProposalJuly 16, 2025 | globenewswire.comVincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - MorningstarJuly 9, 2025 | morningstar.comMVincerx Pharma, Inc. Common Stock (VINC) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comSee More Vincerx Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vincerx Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vincerx Pharma and other key companies, straight to your email. Email Address About Vincerx PharmaVincerx Pharma (NASDAQ:VINC) is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company’s research programs combine small-molecule therapeutics with antibody-drug conjugates designed to selectively deliver treatment to diseased cells. Vincerx’s pipeline has included VIP152, an investigational cyclin-dependent kinase 9 inhibitor being studied as a potential treatment for hematologic malignancies and solid tumors, and VIP943, an antibody-drug conjugate targeting CD123 for certain blood cancers. These candidates remain investigational and have not been approved for commercial use. Vincerx Pharma was founded in 2019 and is based in Palo Alto, California. The company’s operations and clinical development activities have been focused primarily on oncology, with studies conducted through research and clinical networks serving patients in the United States and other regions. Ahmed Hamdy, M.D., has served as a co-founder and chief executive officer.View Vincerx Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
